Fabio De Oliveira Vianna
๐Ÿ’Š The Pill That Changed the Game (Again) + Portfolio Update ๐Ÿ“ˆ Big moves today. Novo Nordisk is up more than 5% ๐Ÿš€ after the news that their oral weight-loss pill is finally live in the US. Why this matters: The Catalyst: This is the first oral GLP-1 pill for weight loss to hit the US market. Itโ€™s a massive competitive advantage (head start) over rivals like Eli Lilly, whose oral option is still down the road. The Numbers: NVO has had a tough year (down ~40% from highs), but this is the "redemption" arc. P/E: Trading around 15x, which is attractive for a company with this kind of moat. Margins: Gross margins remain elite at ~83%, with operating margins near 49%. This is a cash flow monster. ๐Ÿ’ธ ๐Ÿ’ผ Portfolio Update: While the market is volatile, our strategy is working. Our portfolio is already up 3.6% this year. ๐Ÿ“ˆโœ… ๐Ÿ›ก๏ธ Defensive Moves: Iโ€™m not just chasing growth; Iโ€™m locking in safety. Procter & Gamble (PG): I bought yesterday. Itโ€™s the ultimate defensive stockโ€”steady cash flow and reliable dividends. ๐Ÿงผ๐Ÿ’ฐ Nestlรฉ (NESN.SW): I am buying this dip. ๐Ÿ“‰ The stock has taken a hit recently, but at these levels, the valuation for a global staple giant is too good to ignore. The Strategy: Aggressive on catalysts ($NOVO $NOVO-B.CO (Novo Nordisk B A/S) defensive on staples ($PG, $NESN.ZU (Nestle SA) Balance is key. โš–๏ธ $NSDQ100 $SILVER
null
.